Xcelience Makes Investment in Powdersize
PTSM: Pharmaceutical Technology Sourcing and Management
Investment in Powdersize adds particle-size control solutions to Xcelience’s capabilities.
Xcelience, a contract development and manufacturing organization, announced on July 31, 2015 that it has made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization and powder-size classification for the pharmaceutical industry. This investment was made to grow Powdersize’s business and add particle-size control solutions to Xcelience’s capabilities, the company reported in a press statement.
Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues. Current industry trends increasingly demand micronization of APIs with particle sizes of 1-10µm, Xcelience reports.
Powdersize will continue with expansion plans in a recently added facility, to support the additional business expected with the integration and shared development projects.
Source: Xcelience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
